Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more


Novo Nordisk A/S: Saxenda® demonstrated improvements in BMI and body weight in a ... Read more


Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more


Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

Reliable supply of medicines

COVID-19 contributions

31 March - During the global coronavirus outbreak, Novo Nordisk’s key priority is to safeguard the continued supply of our lifesaving medicines to patients.

The situation is continually evolving, but currently we are not experiencing any supply constraints. We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.

Read Lars Fruergaard Jørgensen's perspective on how we are contributing to the fight against COVID-19

Updates on Novo Nordisk's latest contributions and initiatives


Novo Nordisk and UNICEF partner to help prevent childhood overweight and obesity

20 November - Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.

Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.

“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard Jørgensen.

Read the full press release on the partnership

Read UNICEF's release


The technology behind tablets

production Denmark

What if medicines injected by millions could be delivered in tablets? After almost 100 years of delivering injectable therapies, Novo Nordisk’s R&D team is finding answers to this enduring question. Chief Science Officer Mads Krogsgaard Thomsen is leading the way and he reflects on the magnitude of the scientific challenge and the progress made in his laboratories.

Read Mads' reflections


Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact 

Circular for zero

Novo Nordisk intends to achieve the target to use only renewable electricity in its global production facilities by 2020. The announcement on 30 April followed a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about Circular for Zero and download the full press release on the environmental ambitions 


Red Cross and Novo Nordisk partner to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership



Financial Results, first quarter
06MayCopenhagen, Denmark

Annual Report 2019

Novo Nordisk in brief

Financial results 2020

6 May - first quarter

6 August - first 6 months

30 October - first 9 months


When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years. 

Watch the documentary, 'Safely in the Rainbow', on YouTube